Karyopharm Therapeutics Inc. (KPTI) is priced at $9.69 after the most recent trading session. At the very opening of the session, the stock price was $10.24 and reached a high price of $10.38, prior to closing the session it reached the value of $10.20. The stock touched a low price of $9.64.
Recently in News on April 1, 2021, Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4). Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Compensation Committee of Karyopharm’s Board of Directors granted stock options to purchase an aggregate of 150,600 shares of Karyopharm’s common stock to 15 newly-hired employees, with a grant date of March 31, 2021. The stock options were granted as inducements material to the new employees entering into employment with Karyopharm in accordance with Nasdaq Listing Rule 5635(c)(4). You can read further details here
Karyopharm Therapeutics Inc. had a pretty Dodgy run when it comes to the market performance. The 1-year high price for the company’s stock is recorded $18.00 on 01/05/21, with the lowest value was $9.64 for the same time period, recorded on 04/15/21.
Karyopharm Therapeutics Inc. (KPTI) full year performance was -53.10%
Price records that include history of low and high prices in the period of 52 weeks can tell a lot about the stock’s existing status and the future performance. Presently, Karyopharm Therapeutics Inc. shares are logging -62.70% during the 52-week period from high price, and -0.36% higher than the lowest price point for the same timeframe. The stock’s price range for the 52-week period managed to maintain the performance between $9.73 and $25.98.
The company’s shares, operating in the sector of Healthcare managed to top a trading volume set approximately around 4106742 for the day, which was evidently higher, when compared to the average daily volumes of the shares.
When it comes to the year-to-date metrics, the Karyopharm Therapeutics Inc. (KPTI) recorded performance in the market was -37.40%, having the revenues showcasing -35.87% on a quarterly basis in comparison with the same period year before. At the time of this writing, the total market value of the company is set at 736.05M, as it employees total of 432 workers.
Specialists analysis on Karyopharm Therapeutics Inc. (KPTI)
During the last month, 0 analysts gave the Karyopharm Therapeutics Inc. a BUY rating, 0 of the polled analysts branded the stock as an OVERWEIGHT, 0 analysts were recommending to HOLD this stock, 0 of them gave the stock UNDERWEIGHT rating, and 0 of the polled analysts provided SELL rating.
According to the data provided on Barchart.com, the moving average of the company in the 100-day period was set at 14.16, with a change in the price was noted -6.03. In a similar fashion, Karyopharm Therapeutics Inc. posted a movement of -38.36% for the period of last 100 days, recording 2,546,898 in trading volumes.
Total Debt to Equity Ratio (D/E) can also provide valuable insight into the company’s financial health and market status. The debt to equity ratio can be calculated by dividing the present total liabilities of a company by shareholders’ equity. Debt to Equity thus makes a valuable metrics that describes the debt, company is using in order to support assets, correlating with the value of shareholders’ equity The total Debt to Equity ratio for KPTI is recording 3.78 at the time of this writing. In addition, long term Debt to Equity ratio is set at 3.78.
Trends and Technical analysis: Karyopharm Therapeutics Inc. (KPTI)
Raw Stochastic average of Karyopharm Therapeutics Inc. in the period of last 50 days is set at 0.65%. The result represents downgrade in oppose to Raw Stochastic average for the period of the last 20 days, recording 1.71%. In the last 20 days, the company’s Stochastic %K was 10.11% and its Stochastic %D was recorded 10.37%.
Now, considering the stocks previous presentation, multiple moving trends are noted. Year-to-date Price performance of the company’s stock appears to be encouraging, given the fact the metric is recording -37.40%. Additionally, trading for the stock in the period of the last six months notably deteriorated by -38.48%, alongside a downfall of -53.10% for the period of the last 12 months. The shares increased approximately by -4.44% in the 7-day charts and went up by -22.51% in the period of the last 30 days. Common stock shares were lifted by -35.87% during last recorded quarter.